Education
About Us
Working with TipRanks
Follow Us
PolyPid Ltd. (PYPD)
:PYPD
Top Page
PolyPid
(NASDAQ:PYPD)
Select Model
Select Model
Rating:41Neutral
Price Target:―
PolyPid's score reflects significant financial challenges, including consistent losses and negative equity. While the company's clinical advancements and financing efforts are promising, they are not sufficient to offset the financial risks. The stock exhibits neutral technical indicators and an unattractive valuation, limiting its appeal to investors.
Positive Factors
Clinical Trial Progress
The positive recommendation from the DSMB indicates promising efficacy signals for D-PLEX100, enhancing its potential for regulatory approval and commercialization.
Financing and Cash Runway
The successful financing extends operational runway, providing financial stability to advance clinical trials and regulatory activities.
Market Potential for D-PLEX100
The large addressable market for D-PLEX100 in surgical procedures offers significant revenue potential upon successful commercialization and approval.
Negative Factors
Consistent Financial Losses
Ongoing financial losses highlight challenges in achieving profitability, which could impact long-term sustainability and require continued external financing.
Negative Equity
Negative equity suggests solvency issues, limiting financial flexibility and increasing reliance on external funding to support operations.
Increased R&D Expenses
Rising R&D costs, while necessary for product development, exacerbate financial strain and may delay the path to profitability if not managed effectively.
PolyPid (PYPD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$35.16M
Dividend YieldN/A
Average Volume (3M)54.38K
Price to Earnings (P/E)―
Beta (1Y)0.03
Revenue GrowthN/A
EPS Growth61.18%
CountryUS
Employees57
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.78
Shares Outstanding10,190,904
10 Day Avg. Volume41,113
30 Day Avg. Volume54,379
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.07
Forecast
1Y Price Target
$11.50Price Target Upside241.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
PolyPid Business Overview & Revenue Model
Company DescriptionPolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
How the Company Makes MoneyPolyPid generates revenue primarily through the development and commercialization of its proprietary PLEX technology, which facilitates the extended release of drugs at surgical sites. The company's revenue model is focused on advancing its product pipeline through clinical trials towards regulatory approval and subsequent commercialization. Revenue streams include potential sales of its lead product candidate D-PLEX100 upon approval, as well as future licensing and partnership deals with other pharmaceutical companies. These partnerships may involve co-development, marketing, and distribution agreements, enhancing PolyPid's market reach and revenue potential.
PolyPid Earnings Call Summary
Earnings Call Date:Aug 13, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 05, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant positive developments, including successful trial results for D-PLEX100 and a strengthened financial position, despite increased expenses and technical issues during the call.Q2-2025 Updates
Positive Updates
Successful SHIELD II Phase III Trial Results
The SHIELD II Phase III trial demonstrated significant clinical benefits of D-PLEX100 in preventing surgical site infections (SSIs) in abdominal colorectal surgeries, with a statistically significant reduction of 38% in the primary endpoint and a 58% reduction in the rate of SSIs.
Strong Financial Position
PolyPid strengthened its balance sheet with cash and cash equivalents of $17.4 million and short-term deposits of $12 million, totaling $29.5 million, a significant improvement from $15.6 million as of December 31, 2024.
Positive Reception and Partnership Interest
D-PLEX100 generated substantial interest from potential commercial partners, healthcare professionals, and thought leaders, and there's increased interest from potential partners following Phase III results.
Progress in GLP-1 Program
Significant progress was made on the GLP-1 program aimed at addressing metabolic diseases, representing an exciting opportunity to expand PolyPid's therapeutic footprint.
Negative Updates
Increased Expenses and Net Loss
Research and development expenses increased to $6.2 million from $4.8 million in Q2 2024, and the net loss widened to $10 million compared to $6.3 million in the same period of 2024.
Technical Issues During Call
Technical difficulties occurred during the call, affecting communication and potentially impacting the clarity of certain responses.
Company Guidance
During PolyPid's second quarter 2025 earnings call, the company provided several key metrics and guidance for its D-PLEX100 program and financial outlook. The SHIELD II Phase III trial results demonstrated a 58% reduction in surgical site infections (SSI) compared to the standard of care, with significant reduction in deep SSIs. The trial also showed a 62% reduction in patients with an ASEPSIS score over 20, indicating less severe infection appearances. PolyPid plans to submit a New Drug Application (NDA) to the FDA in early 2026 and a Marketing Authorization Application (MAA) in Europe shortly thereafter. Financially, the company improved its cash position to $29.5 million as of June 30, 2025, and expects its cash runway to extend well into 2026. The company also announced progress in its GLP-1 program aimed at the metabolic disease market, and it anticipates further developments in partnership discussions and commercialization preparations for D-PLEX100.PolyPid Financial Statement Overview
Summary
PolyPid's financial health is concerning with no revenue generation, consistent losses, and negative equity. The company is highly reliant on external financing to maintain operations, which poses a risk to sustainability.Income Statement
PolyPid has consistently reported no revenue over the past five years, indicating challenges in commercializing its products. The gross and net profit margins are negative, reflecting significant losses. EBIT and EBITDA margins are also unfavorable, suggesting ongoing operational inefficiencies.10
Very Negative
Balance Sheet
The company exhibits a concerning financial structure with negative stockholders' equity in the latest year, indicating that liabilities exceed assets. The debt-to-equity ratio is not applicable due to negative equity, but the overall high level of debt relative to assets suggests potential solvency issues.15
Very Negative
Cash Flow
PolyPid's cash flow shows negative operating cash flow and free cash flow, indicating insufficient cash generation from operations. This trend persists over the years, albeit with some improvement in recent years. However, reliance on financing activities to support cash needs poses a risk.20
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -1.62M | -1.82M | -1.72M | -1.12M | -1.01M |
| EBITDA | -22.87M | -25.83M | -20.26M | -36.37M | -41.48M | -35.86M |
| Net Income | -23.86M | -29.02M | -23.86M | -39.52M | -40.71M | -35.32M |
Balance Sheet | ||||||
| Total Assets | 15.37M | 25.22M | 15.37M | 25.97M | 44.23M | 75.85M |
| Cash, Cash Equivalents and Short-Term Investments | 5.61M | 15.64M | 5.61M | 12.59M | 32.20M | 44.48M |
| Total Debt | 11.78M | 9.62M | 11.78M | 13.73M | 0.00 | 0.00 |
| Total Liabilities | 17.47M | 17.54M | 17.47M | 20.11M | 8.01M | 3.07M |
| Stockholders Equity | -2.10M | 7.68M | -2.10M | 5.86M | 36.23M | 72.78M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -22.04M | -17.43M | -36.08M | -35.38M | -22.77M |
| Operating Cash Flow | 0.00 | -21.96M | -17.24M | -34.32M | -32.39M | -21.60M |
| Investing Cash Flow | 0.00 | -330.00K | 3.80M | 16.57M | 36.90M | -40.77M |
| Financing Cash Flow | 0.00 | 32.42M | 9.98M | 16.43M | 1.03M | 62.77M |
PolyPid Technical Analysis
Negative
3.37
Price Trends
3.47
Negative
3.33
Positive
3.11
Positive
Market Momentum
>-0.01
Positive
44.96
Neutral
35.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PYPD, the sentiment is Negative. The current price of 3.37 is below the 20-day moving average (MA) of 3.43, below the 50-day MA of 3.47, and above the 200-day MA of 3.11, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.96 is Neutral, neither overbought nor oversold. The STOCH value of 35.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PYPD.
PolyPid Risk Analysis
PolyPid disclosed 78 risk factors in its most recent earnings report. PolyPid reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PolyPid Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
48 Neutral | 32.25M | -2.51 | -123.35% | ― | 248.62% | 26.22% | |
46 Neutral | 42.87M | -3.74 | ― | ― | ― | 32.31% | |
45 Neutral | 66.13M | -0.47 | -72.83% | ― | -60.16% | ― | |
41 Neutral | $35.16M | ― | -312.77% | ― | ― | 61.18% | |
41 Neutral | 36.42M | -1.29 | 339.81% | ― | 309.82% | 11.80% | |
40 Underperform | 8.22M | -0.35 | -76.48% | ― | -2.06% | 64.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
PYPD
PolyPid
3.37
-0.25
-6.91%
PLUR
Pluri
4.54
-1.54
-25.33%
CLGN
Collplant Holdings
2.83
-2.10
-42.60%
GRCE
Grace Therapeutics
3.08
-0.04
-1.28%
VYNE
VYNE Therapeutics
0.32
-1.52
-82.61%
ALGS
Aligos Therapeutics
9.36
1.32
16.42%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.